Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 7:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2665–2688 of 18,757 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Phase I Clear all

Conditions: Breast Neoplasms, Neoplasm Metastasis
Interventions: CodaLytic; Biological
Lead sponsor: Codagenix, Inc; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Boston, Massachusetts • Canton, Ohio

Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Burkitt Lymphoma, Diffuse Large Cell Lymphoma, Gray Zone Lymphoma, Lymphoblastic Lymphoma, Anaplastic Large Cell Lymphoma, Hodgkin Lymphoma
Interventions: CPX-351; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 12 Months to 30 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy
Interventions: Sitaxentan sodium/Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Glendale, California

Conditions: Solid Tumor, Adult
Interventions: HTI-1066 dose level 1, HTI-1066 dose level 2, HTI-1066 dose level 3, HTI-1066 dose level 4; Drug
Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Scottsdale, Arizona • Nashville, Tennessee • Houston, Texas

Conditions: Gulf War Syndrome
Interventions: Curcumin, Glutathione, Placebo; Drug · Other
Lead sponsor: South Florida Veterans Affairs Foundation for Research and Education; Federal
Eligibility: 35 Years to 70 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy
Interventions: MEDI-528 0.3 mg/kg, MEDI-528 1 mg/kg, MEDI-528 3 mg/kg, MEDI-528 9 mg/kg; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 19 Years to 49 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 2
States / cities: New Orleans, Louisiana • Lincoln, Nebraska

Conditions: Solid Tumor, Advanced Cancer, Metastatic Cancer, Non Small Cell Lung Cancer, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Pancreatic Cancer, Triple Negative Breast Cancer, Head and Neck Cancer
Interventions: MEM-288 Intratumoral Injection, Nivolumab, Docetaxel; Biological · Drug
Lead sponsor: Memgen, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 2
States / cities: Tampa, Florida • Durham, North Carolina

Conditions: Leukemia, Myeloid, Acute
Interventions: DFP-10917, Venetoclax; Drug
Lead sponsor: Delta-Fly Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 4
States / cities: Orange, California • Winston-Salem, North Carolina • Burlington, Vermont + 1 more

Conditions: Hematologic Malignancies
Interventions: Allogeneic donor TCRαβ+/CD19+ cell-depleted peripheral blood mononuclear cells; Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 80 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Hypertension
Interventions: baxdrostat; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 5
States / cities: Rialto, California • Miami, Florida • Orlando, Florida + 2 more

Conditions: Healthy
Interventions: PF-04965842, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Renal Cell Carcinoma
Interventions: Belzutifan, Palbociclib; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Chicago, Illinois • Boston, Massachusetts + 1 more

Conditions: Pharmacokinetics
Interventions: AZD9742, Diltiazem, ketoconazole; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 23 Years to 45 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Respiratory Syncytial Virus Infections
Interventions: RSV LID cp ΔM2-2 Vaccine, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 24 Months
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: Baltimore, Maryland • Laurel, Maryland

Conditions: Pharmacokinetics
Interventions: Fulvestrant for Injectable Suspension, Faslodex (Reference); Drug
Lead sponsor: Eagle Pharmaceuticals, Inc.; Industry
Eligibility: 40 Years to 75 Years · Female only
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 12
States / cities: Long Beach, California • DeLand, Florida • Miami, Florida + 7 more

Conditions: Gastroenteritis Norovirus
Interventions: Norovirus GII.4 Challenge Pool CIN-1, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Advanced or Metastatic Solid Tumors
Interventions: IPH4502; Drug
Lead sponsor: Innate Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 5
States / cities: Boston, Massachusetts • Hackensack, New Jersey • New York, New York + 2 more

Conditions: Gout, Hyperuricemia
Interventions: Uricase-PEG 20; Biological
Lead sponsor: EnzymeRx; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Miami, Florida • Duncansville, Pennsylvania

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
Interventions: Biopsy, Biospecimen Collection, Celecoxib, Computed Tomography, Interferon Alpha-2, Magnetic Resonance Imaging, Pembrolizumab, Rintatolimod; Procedure · Drug · Biological
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Cancer, Pancreatic Cancer, Pancreatic Carcinoma
Interventions: CPI-613, Gemcitabine; Drug
Lead sponsor: Cornerstone Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 2
States / cities: The Bronx, New York • Dallas, Texas

Conditions: Advanced Solid Tumors, Metastatic Breast Cancer, Metastatic Renal Cell Carcinoma
Interventions: RAD001 + BEZ235; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 3
States / cities: Fayetteville, Arkansas • St Louis, Missouri • Charleston, South Carolina

Conditions: Influenza
Interventions: MEDI8852, Placebo; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: HNSCC
Interventions: Tipifarnib, Alpelisib; Drug
Lead sponsor: Kura Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 11
States / cities: Duarte, California • Orlando, Florida • Baltimore, Maryland + 7 more

Conditions: Advanced Urothelial Carcinoma, Oral Drug Administration, Open Label
Interventions: FX-909, Pembrolizumab (KEYTRUDA ®), KEYTRUDA ®( Pembrolizumab); Drug
Lead sponsor: Flare Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 12
States / cities: San Francisco, California • New Haven, Connecticut • Miami, Florida + 7 more

Search by objective public record fields.

A Study of CodaLytic, an Intratumoral Oncolytic Virus, in Patients With Breast Cancer

Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma

Phase 1, Single and Multiple Doses Study of Sitaxentan in Japanese and Western Subjects

Safety and Tolerability of HTI-1066 in Subjects With Advanced Solid Tumors

Glutathione vs. Curcumin Clinical Trial

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single-Dose Subcutaneous Administration of MEDI-528

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia

Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies

Phase 1 PK Study to Evaluate the PK of CIN-107 in Subjects With Hepatic Impairment

First-in-Human Study to Evaluate Safety and Tolerability of Single and Multiple Ascending Doses of Janus Kinase-1 Inhibitor PF-04965842 in Healthy Western and Japanese Subjects

A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)

Open Label Study, Assessing the Effect of Diltiazem or Ketoconazole on the Pharmacokinetics of AZD9742 in Healthy Volunteers

Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants and Children 6 to 24 Months of Age

Study to Evaluate the Safety, Tolerability, and PK of Fulvestrant After IM Administration

Phase I Study to Determine the Optimal Human Challenge Dose for a Norovirus GII.4 Challenge Stock (CIN-1)

Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors

Safety and Efficacy Study of Intravenous Uricase-PEG 20

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients

Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors

Phase 1 Placebo-controlled,Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of MEDI8852 in Adults

Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma